Improvement of Laboratory Diagnostics in Hypothyroid Patients Using Levothyroxine
A legfontosabb adatok
- Ki végzi
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
- Hol
- Hollandia1 helyszín, 1 országbanVálassz országot a helyszínekhez
- Azonosító
- Állapot
- Toboroz
- Résztvevők
- 500 fő, tervezett
- Kezdés
- 2022. júl. 26.
- Tervezett befejezés
- 2026. jún.
- A vizsgálat típusa
- Megfigyeléses, 5 csoport
- A vizsgált kezelések
- Single extra blood draw and completion of single questionnaire
- Single blood draw and completion of single questionnaire
- A regiszteradat frissítve
- 2025. október 3.
Ki vehet részt
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.
The trial is looking for adults with hypothyroidism (an underactive thyroid) who take levothyroxine, and also healthy volunteers. Each person gives one blood sample and fills in one questionnaire.
- Életkor
- 18 Years to 100 Years
- Nem
- All sexes
- A betegség stádiuma
- Patients must have one of these: primary hypothyroidism (such as Hashimoto's), hypothyroidism after total thyroid removal for thyroid cancer, L-T4 use due to treatment of Graves' disease, or central hypothyroidism. Their doctor must judge their thyroid levels to be normal or on target. Healthy volunteers must consider themselves healthy. All must speak and understand Dutch or English.
- Korábbi kezelés
- Patients must take a stable dose of levothyroxine. Healthy volunteers cannot take thyroid medicine.
- Biomarker vagy leletérték
- Patients with Graves' disease: TSH within 0,5-5,0 mU/L. Central hypothyroidism: normal fT4 (reference interval 12-22 pmol/L), as judged by the doctor.
A részvétel fő kizáró okai
- Pregnancy
- Thyroid levels not normal according to the doctor, or TSH still suppressed in Graves' disease
- Taking liothyronine (Cytomel), iodide or oral contraceptives
- Active cancer treatment (other than thyroid cancer for patients)
- Healthy volunteers: taking lithium, amiodarone, propranolol, glucocorticoids, heparin or growth hormone
A regiszter feltételei, szó szerint
Mind a 15 feltétel megnézéseKevesebb
Ki vehet részt
- In order to be eligible to participate in this study, a hypothyroid subject must meet all of the following criteria:
- Ability to provide informed consent
- Ability to speak and understand Dutch or English
- Intake of a stable dosage of levothyroxine, meaning the dosage of levothyroxine must not be changed during the appointment at the outpatient clinic
- Diagnosis of one these forms of hypothyroidism; Patients with primary hypothyroidism: euthyroid based on TSH according to physician; Patients with hypothyroidism after a total thyroidectomy due to thyroid carcinoma (therefore athyroid): on target TSH according to physician (target TSH depending on stage/severity of carcinoma); Patients using L-T4 due to therapy of Graves' disease: euthyroid based on TSH according to physician (TSH cannot be suppressed, namely TSH within reference interval of 0,5-5,0 mU/L); Patients with central hypothyroidism: euthyroid based on fT4 according to physician (common is fT4 in the upper limit, reference interval is 12-22 pmol/L); In order to be eligible to participate in this study, a healthy control subject must meet all of the following criteria:
- Ability to provide informed consent
- Ability to speak and understand Dutch or English
- Consider themselves healthy
Ki nem vehet részt
- Patients using L-T4 due to therapy of Graves' disease: if TSH is still suppressed
- Any of the following medication; Liothyronine (Cytomel); Iodide; Oral contraceptives; Active treatment of malignancy (other than thyroid carcinoma); A potential healthy control subject who meets any of the following criteria will be excluded from participation in this study:
- Any of the following medication; Thyroid medication (a.o. levothyroxine, thiamazol, PTU); Lithium; Amiodarone; Propranolol; Iodide; Glucocorticoids; Oral contraceptives; Heparin; Growth hormone; Active treatment of malignancy
- A potential hypothyroid subject who meets any of the following criteria will be excluded from participation in this study:
- Not euthyroid according to physician
- Pregnancy
- Pregnancy
A fő feltételek kérdésként
Magadról válaszolj. Ez nem döntés: hogy részt vehetsz-e, azt csak a vizsgálat csapata mondhatja meg.
- 18 és 100 év között vagy?
Ez a vizsgálat jelenleg itt érhető el: Hollandia.
Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.
A vizsgálatról
Mit akar kideríteni a vizsgálat
Hypothyroidism is a thyroid disorder and one of the most common endocrine disorders. Hypothyroidism can have multiple causes; most patients suffer from primary autoimmune hypothyroidism (Hashimoto's disease), but also central hypothyroidism, hypothyroidism after total thyroidectomy due to thyroid carcinoma, or hypothyroidism due to therapy of Graves' disease occur. Most patients with hypothyroidism are treated with levothyroxine (L-T4) to supplement the lack of thyroxine (T4) produced by their own thyroid. Serum thyroid-stimulating hormone (TSH) and/or free T4 (fT4) are currently measured to assess the efficacy of this therapy and to establish euthyroidism. It is known that fT4 concentrations in patients using L-T4 can be above the upper limit of the reference interval, while their TSH is not (completely) suppressed. This raises the question whether fT4 is an accurate reflection of thyroid hormone status in patients using L-T4. TSH is considered a reliable parameter of thyroid hormone status; however, TSH cannot be used to assess thyroid function in specific hypothyroid patient groups (e.g. central hypothyroidism). Free triiodothyronine (fT3), the active thyroid hormone, has been suggested to be an interesting alternative of fT4 to assess thyroid function. Previously, the methods to measure fT3 were not that robust; however, methods to determine fT3 have been improved, are currently reliable and not susceptible to changes due to L-T4 intake. In addition, the fT3/fT4 ratio is thought to be an interesting candidate in assessing thyroid hormone status as well. The aim of this study is to improve laboratory diagnostics of thyroid hormone status in patients with hypothyroidism receiving L-T4 in whom TSH cannot be used as a reflection of thyroid hormone status. We will primarily investigate the additional already available laboratory tests fT3 and fT3/fT4 ratio. We hypothesize that treated hypothyroid participants who are assumed euthyroid based on TSH (e.g. patients with Hashimoto's hypothyroidism) but have fT4 concentrations above the upper reference limit will more often have a fT3 level or a fT3/fT4 ratio within the reference interval. Concentrations of alternative markers in healthy controls and patients with Hashimoto's hypothyroidism with 'normal' TSH concentrations can, thus, be used to predict thyroid hormone status in patients using L-T4 in whom TSH cannot be used to assess thyroid hormone status.
A vizsgálat 5 csoportja
- Hashimoto's hypothyroidism
Group of 100 patients with Hashimoto's hypothyroidism using levothyroxine
Kezelés: Single extra blood draw and completion of single questionnaire
- Hypothyroidism after thyroidectomy after thyroid carcinoma
Group of 100 patients with hypothyroidism after thyroidectomy after thyroid carcinoma using levothyroxine
Kezelés: Single extra blood draw and completion of single questionnaire
- Central hypothyroidism
Group of 100 patients with central hypothyroidism using levothyroxine
Kezelés: Single extra blood draw and completion of single questionnaire
- Hypothyroidism during treatment for Graves' Disease
Group of 100 patients with hypothyroidism during treatment for Graves' Disease using levothyroxine
Kezelés: Single extra blood draw and completion of single questionnaire
- Healthy controls
100 healthy euthyroid controls
Kezelés: Single blood draw and completion of single questionnaire
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- MI-összefoglaló
- A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
- Kérdések a feltételekről
- Forrás: NCT06083636: ki vehet részt
- A regiszteradat frissítve
- 2025. október 3.